Summary: Cagrilintide and retatrutide are investigational injectable medicines being studied for obesity and type 2 diabetes in men, targeting multiple hormonal pathways to reduce appetite, improve blood glucose control, and increase energy expenditure, but neither is currently licensed in the UK
While this additive effect might seem beneficial, unmonitored combination therapy can lead to dangerously low blood glucose levels
While some providers may see microdosing as a way to ease patients into treatment or reduce side effects, others worry about its risks
That is encouraging because it suggests stronger fat loss does not necessarily come with disproportionately worse lean-mass loss
Many Canadians use their family physician for routine labs or access walk-in clinics that offer direct-pay bloodwork panels
Furthermore, owing to the single-blind design, these results should not be treated as evidence of symptomatic or disease-modifying efficacy of exenatide [17]